Loading
A phase 1/2 trial of HDP-101 in multiple myeloma, run by Heidelberg Pharma AG, now recruiting.
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT04879043 by Heidelberg Pharma AG, with 78 participants planned, started 2022-02-07 and due to reach its primary completion in 2028-03. Interventions recorded: HDP-101.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/